Coronavirus (COVID-19) Statement

We continue to closely monitor the situation surrounding the COVID-19 pandemic and are following the published recommendations of the CDC and the American Academy of Ophthalmology. We will continue to see our patients and treat any urgent/emergent needs.

With all of our offices open, the following protocols are in place:

1) We have greatly expanded measures to disinfect our office including cleaning between each patient appointment.

2) To limit any potential exposure, we ask you NOT to bring any non-essential person(s) with you to the appointment.

3) If someone must accompany you to your appointment, we ask that they do not enter the office, if at all possible.

4) If you have an upcoming appointment and identify with the following statements, please do not come directly to the office, but instead call us:

• Fever greater than 100.4

• Respiratory symptoms or difficulty breathing

• Exposed to someone with COVID-19 in the past 14 days

• Placed in self/hospital quarantine by medical doctor

 Your health and that of our staff is our guiding priority and we continue to update our protocol to ensure safety for everyone. If you have questions regarding these evolving protocols, please contact our office.

Dr. Fox CURRICULUM VITAE

Gregory M. Fox, M.D., F.A.C.S.
 

WORK HISTORY

May 1, 1999 -PRESENT:

  • Retina Associates, LLC
    Santa Fe Medical Building
    9301 West 74th Street
    Suite 210
    Shawnee Mission, KS 66204
  • Retina Associates, LLC
    6201 College Boulevard
    Suite 200
    Overland Park, KS 66211
  • Retina Associates. LLC
    4100 North Mulberry Drive
    Suite 100
    Kansas City, MO 64116
  • Retina Associates, LLC
    6001 SW 6th Avenue
    Suite 300
    Topeka, KS 66615
  • Retina Associates, LLC
    3700 West 10th Street
    Suite 101
    Sedalia, MO 65301
  • Retina Associates, LLC
    100 NE Missouri Road
    Suite 203
    Lee's Summit, MO 64086
     

1998 – 2002:

  • Hunkeler Eye Center
    NovaMed Eye Surgery Center
    4321 Washington #6000
    Kansas City, Missouri

1997 – 1998:

  • Clinical Instructor, Active Staff
    Allegheny University Hospital – MCP
    Philadelphia, Pennsylvania
  • Active Staff
    St. Francis Hospital
    Wilmington, Delaware
  • Active Staff
    Medical Center of Delaware
    Wilmington, Delaware
  • Consulting Staff Physician
    St. Christopher’s Hospital
    Philadelphia, Pennsylvania

1994 – 1997:

  • Medical Officer
    Branch of Ophthalmic Devices
    Food and Drug Administration (FDA)
    Rockville, Maryland
  • Special Volunteer Staff
    Laboratory of Immunology Clinical Branch
    National Eye Institute
    Bethesda, Maryland

1993 – 1997:

  • Vitreoretinal Surgeon
    Department of Ophthalmology
    National Naval Medical Center
    Bethesda, Maryland
  • Assistant Professor of Surgery
    Uniformed Services University of Health Sciences
    Bethesda, Maryland

EDUCATION

  • Saguaro High School
    Scottsdale Arizona
  • University of Notre Dame
    South Bend, Indiana
  • University of Michigan Medical School
    ​Ann Arbor, Michigan

POSTDOCTORAL TRAINING

  • William Beaumont Hospital
    Royal Oak, Michigan
    Resident Transitional Intern
  • Bascom Palmer Eye Institute
    Miami, Florida
    Ophthalmology Resident
  • Bascom Palmer Eye Institute
    Miami, Florida
    Medical Retina Fellow
  • William Beaumont Hospital
    Royal Oak, Michigan
    Vitreo/Retinal Fellow
                       

LICENSURE

  • Missouri State License
  • Kansas State License
  • Michigan State License

BOARD CERTIFICATIONS

  • Diplomate, American Board of Ophthalmology (1992)
  • Diplomate, National Board of Medical Examiners (1988)

ORGANIZATIONS AND SOCIETIES

  • American Academy of Ophthalmology
  • American Uveitis Society
  • Umbo Society
  • Society of Military Ophthalmologists
  • Association for Research in Vision and Ophthalmology
  • Phi Beta Kappa
  • Executive Committee, Delaware Ophthalmologic Society
  • Medical Society of Delaware
  • Medical Advisory Committee, Blue Cross Blue Shield of Kansas City
  • Fellowship of American College of Surgeons
  • Kansas Medical Society
  • Kansas City Medical Society
  • Kansas Society of Eye Physicians and Surgeons
  • Missouri Society of Eye Physicians and Surgeons
  • Kansas City Society of Ophthalmology and Otolaryngology
  • Kansas City Society of Ophthalmology and Otolaryngology Journal Club
  • American Society of Retina Surgeons
  • Missouri State Medical Association

CLINICAL RESEARCH

  • Alcon: C-04-59, Sub-Investigator, Interval Dose Evaluation of Anecortave Acetate for Those with Neovascular AMD, 01/2005 – 02/2008.
  • Alcon: C-02-60, Sub-Investigator, Posterior Juxtascleral Injection of Anecortave Acetate versus Sham for Inhibition of CNV in Non-Exudative AMD, 01/2004 - 01/2009.
  • Alcon: C-01-99, Principal Investigator, Posterior Juxtascleral Injection of Anecortave Acetate versus Visudyne for Subfoveal Exudative AMD, 08/2003 - 08/2005.
  • Alcon: C-12-006, Sub-Investigator, Eylea vs ESBA1008 for the Treatment of Exudative Age-Related Macular Degeneration, 3/2013 - 1/2014.
  • Alcon: RTH258-C001, Sub-Investigator RTH258 versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration, 05/2015 - 05/2018.
  • Allergan: 206207-008, Sub-Investigator, Posurdex Retinal Vein Occlusion, 1/2005 – 02/2009.
  • Allergan: 206207-010, Sub-Investigator, Posurdex Diabetic Macular Edema, 3/2005 – 03/2013.
  • Allergan: 208397-001, Principal Investigator, AGN-208397 Retinal Vein Occlusion, 11/2010 - 02/2013.
  • DRCR: Intravitreal Triamcinolone Study B, Sub-Investigator, Focal Laser Treatment versus Intravitreal Injection Triamcinolone for Treatment of Diabetic Macular Edema, 6/2005 – 10/2006.
  • DRCR: Protocol T, Principal Investigator, Aflibercept, Bevacizumab and Ranibizumab for the Treatment of Diabetic Macular Edema, 12/2012 - 10/2015.
  • DRCR:  Protocol V, Principal Investigator, Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity, 11/2013 - 08/2018.
  • DRCR:  Protocol U, Principal Investigator, Short-term Evaluation of Combination Corticosteroid + AntiVEGF Treatment for Persistent Central Involved Diabetic Macular Edema Following Anti-VEGF Therapy in Pseudophakic Eyes, 09/2014 - present.
  • DRCR: Protocol AA, Principal Investigator, Peripheral Diabetic Retinopathy Lesions on Ultrawide-field Fundus Images and Risk of Diabetic Retinopathy Worsening Over Time, 07/2014 - present.
  • DRCR: Protocol W, Principal Investigator, Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy, 02/2016 - present.
  • DRCR: Protocol AB, Principal Investigator, Intravitreous Anti-VEGF versus Prompt Vitrectomy for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy , 11/2016 - present.
  • DRCR: Protocol AC, Principal Investigator, Randomized Trial of Intravitreal Afibercept versus Intravitreal Bevacizumab + Deferred Aflibercept for the Treatment of Central-Involved Diabetic Macular Edema.  11/2017 - present.
  • Eli Lilly: Protein Kinase C Inhibitor – Principal investigator; Diabetic Retinopathy Study.
  • Eyetech: EOP1023, Sub-Investigator, Intravitreal Injection of Pegaptanib Sodium Administered Every 6 Weeks for Neovascular Age-Related Macular Degeneration, 09/2005 - 10/2008.
  • Eyetech: PRESERVE, Sub-Investigator, Intravitreal Injection of Pegaptanib Sodium Administered Every 4 Weeks versus 6 Weeks for Diabetic Macular Edema, 09/2009 – 01/2012.
  • Eyetech: EOP1024, Sub-Investigator, Intravitreal Injection of Pegaptanib Sodium Administered Every 6 Weeks for NVAMD, DME, RVO to Assess the Effects on the Corneal Endothelium, 05/2010 - 11/2011
  • Genaera: 301, Sub-Investigator, Squalamine Lactate IV Infusion for Treatment of Neovascular AMD, 9/2005 – 11/2006.
  • Genentech: FVF4165g, Principle Investigator, Intravitreal Injection of Ranibizumab for Branch Retinal Vein Occlusion, 2/2008 –01/2010.
  • Genentech: FVF4166g, Principle Investigator, Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion, 2/2008 –01/2010.
  • Genentech: FVF4168g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Diabetic Macular Edema, 08/2007 – 12/2012.
  • Genentech: FVF3426g, Principal Investigator, Open-Label Extension for Subjects Who Completed a Genentech Sponsored Ranibizumab Study, 03/2009 - 07/2010.
  • Genentech: FVF4295, Principal Investigator, Evaluation of Ranibizumab on Ease of Procedure and Complications in PDR Requiring Vitrectomy, 09/2007 – 01/2009.
  • Genentech: FVF4579g, Principal Investigator, 0.5mg AND 2.0mg Ranibizumab Administered Monthly or PRN for Subfoveal Neovascular Age-Related Macular Degeneration, 06/2009 – 09/2012.
  • Genentech: FVF4967g, Sub-Investigator, Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion, 03/2011 - 01/2013.
  • Genentech: GX29176, Principal Investigator, Study to Assess the Efficacy and Safety of Lampalizumab Administered Inravitreally for Subjects with Geographic Atrophy Secondary to NNVAMD, 11/2014 - 04/2018.
  • Genentech: GX301911, Principal Investigator, Study to Assess the Safety and Tolerability of Lampalizumab Administered Intravitreally for Subjects with Geographic Atrophy Secondary to NNVAMD Who Have Completed a Roche-Sponsored Study, 10/2016 - 04/2018.
  • Genentech: GR40458, Sub-Investigator, Phase III, Active-Comparator Study of the Efficacy, Safety and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration, 11/2018 - present.
  • Genentech: GR40306, Principal Investigator, Phase III, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients With Neovascular Age-Related Macular Degeneration. 03/2019 - present.
  • Genentech: GR40550, Sub-Investigator, Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema.  10/2019 - present.
  • Inspire: Co-Investigator; Intravitreal Injection for Rhegmatogenous Retinal Detachments.
  • Ista: VIT-02-08961X, Principal Investigator; Injections for Severe Vitreous Hemorrhage.
  • Lux BioSciences:  LX211-11, Sub-Investigator, Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects With Active Non-Infectious Uveitis Involving the Intermediate and/or Posterior Segments of the Eye, 1/2011 - 1/2012.
  • MyLan: MYL-1701P-3001, Principal Investigator, Active-Controlled, Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Aflibercept in Subjects With Diabetic Macular Edema, 08/1018 - present.
  • NEI: SCORE2, Sub-Investigator, Study of Comparative Treatments for Retinal Vein Occlusion, 11/2014 - 05/2016
  • Novartis: SMS995-804, Principal investigator; Systemic Injection to Decrease the Rate of Progression to Proliferative Retinopathy in Diabetics.
  • Novartis: CRTH258AUS04, Sub-Investigator, Phase III Study to Assess Safety and Efficacy of Brolucizumab 6mg q4weeks Compared to Aflibercept 2mg q4weeks in Patients With Neovascular Age-Related Macular Degeneration With Persistent Retinal Fluid, 12/2018 - present.
  • Novartis: CRTH258B2301, Sub-Investigator, Phase III Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema, 09/2018 - present.
  • Novartis: CRTH258C2301, Sub-Investigator, Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retina Vein Occlusion, 07/2019 - present.
  • Novartis:  CRTH258C2302, Sub-Investigator, Study to Assess Safety and Efficacy of Broluzizumab versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion.  07/2019 - present.
  • Novartis: CRTH258B2305, Sub-Investigator, Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema, 10/2019 - present.
  • Ophthotech: OPH3000, Sub-Investigator, Trial to Establish the Safety, Tolerability, and Pharmacokinetic Profile of Multiple Intravitreal Injections of Volociximab as Monotherapy or in Combination with Lucentis for NVAMD, 10/2008 - 05/2010.
  • Ophthotech: OPH1001, Sub-Investigator, Trial to Establish the Eficacy of Intravitreal Injections of E10030 Given in Combination with Lucentis for NVAMD, 04/2010 – 11/2011.
  • Ophthotech:  OPH1003, Sub-Investigator, Trial to Establish the Safety and Efficacy of Intravitreal Administration of Fovista Administered in Combination with Lucentis Compared to Lucentis Monotherapy in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration, 10/2013 - 11/2011.
  • Ophthotech:  OPH1004, Sub-Investigator, Intravitreal Fovista Administered in Combination With Either Bevacizumab or Aflibercept Compare to Bevacizumab or Aflibercept Monotherapy in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration, 07/2015 - 09/2017.
  • Ophthea:  OPT-302-1002, Sub Investigator, A Dose-Ranging Study of Intravitreal OPT-3002 in Combination with Ranibizumab, compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration, 12/2017 - 06/019
  • PanOptica: PAN01-101, Sub-Investigator, Study to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Neovascular Age-Related Macular Degeneration, 02/2104 - 03/2016.
  • Prophylactic Treatment of Age-Related Macular Degeneration Study, Principal Investigator; University of Pittsburgh Eye and Ear, Sub-Clinical Diode Laser Treatment of Non-Exudative ARMD.
  • Pharmacia: 524-OPT-0065-002 SnET2 for Exudative ARMD. Principal investigator.
  • Regeneron: R2176-3-AMD-1417, Sub-Investigator, REGN2176-3.  Dose Ranging Co-Formulation of REGN2176-3+Eylea versus Eylea for Subjects With Neovascular Age-Related Macular Degeneration, 06/2015 - 04/2017.
  • Regeneron: R910-3-DME-1518, Sub-Investigator, Intravitreal REGN910-3 for Patients With Diabetic Macular Edema, 05/2016 - 10/2017. 
  • Project in collaboration with the Center for Geriatric Research at Allegheny University, Retinal Pigment Epithelial Transplantation to Compliment Sub-Macular Surgery.
  • Principal Investigator at the National Naval Medical Center for This Collaborative Project with NEI and Washington University, Assessing Patient Preferences for Visual Acuity Loss.
  • Co-Investigator at the National Naval Medical Center, Prospective Evaluation of the Treatment of Fluid Overload in Patients With Diffuse Diabetic Macular Edema.
  • Co-Investigator at the National Naval Medical Center, Treatment of Complex Retinal Detachments With Liquid Perfluorochemicals.
  • Co-Investigator at the National Naval Medical Center, Treatment of Complex Retina Detachments With Silicone Oil.

PUBLICATIONS:

  • Fox GM, Kuwabara TK, Wiggert B, Redmond TM, Hess HH, Chader GJ, Gery I. Autoimmune Uveoretinitis (EAU) Induced by IRBP and by S-Antigen. Clin Immunolol Immunopathol 1987; 43:256-264.
  • Fox GM, Redmond TM, Wiggert B, Kuwabara TK, Chader GJ, Gery I. Dissociation between Lymphocyte Activation for Proliferation and for the Capacity to Adoptively Transfer Uveoretinitis. J Immunol 1987; 138:3242-3246.
  • Gery I, Fox GM, Wiggert B, Redmond TM, Kuwabara TK, Vistica B, Chader GJ. EAU Induced by Interphotoreceptor Retinoid-binding Protein (IRBP: A New Experimental Entity. Modern Trends in Immunology and Immunopathology of the Eye. A Secchi and I Frigona Ed., Milan:Messon 1989; 60-63.
  • Gery I, Hirose S, McAllister C, Fox GM, Wiggert B, Redmond TM, Chader GJ, Kuwabara TK. Difference between the Inflammatory Reactions in the Retina and Pineal Glands in Rats with “EAU”. Trends in Immunology and Immunopathology of the Eye. A Secchi and I Frigona Ed., Milan:Messon 1989; 87-91.
  • Fox GM, Heilskov T, Smith JL. Cogan’s Syndrome and Seroreactivity to Lyme Borreliosis. J Clin Neuro-Ophthalmol 1990; 10:83-87.
  • Fox GM, Joondeph BC, Flynn HW, Pflugfelder SC, Roussel TJ. Delayed Onset Pseudophakic Endophthalmitis. Am J Ophthalmol 1991; 111:163-173.
  • Fox GM, Crouse CA, Chuang EL, et al. Detection of Herpes Virus DNA in Vitreous and Aqueous Specimens. Archives of Ophthalmol 1991; 109:266-271.
  • Lam BL, Sialowski RM, Fox GM, Glaser HS. Visual Loss in Pseudotumor Cerebri from Branch Retinal Artery Occlusion. Am J Ophthalmol 1991; 198:266-271.
  • Fox GM, Flynn HW Jr., Davis JL, Culbertson W. Causes of Reduced Vision in Long-term Follow-up after Surgery for Uveitic Cataract in Patients with Juvenile Rheumatoid Arthritis. Am J Ophthalmol 1992; 114(6):708-714.
  • Fox GM, Blumenkranz MS. Giant Retinal Pigment Epithelial Tears in Acute Retinal Necrosis. Am J Ophthalmol 1993; 116(3):302-306.
  • Fox GM, Blumenkranz MS, Iverson DA. A Better Way to Perform Diabetic Vitrectomy. Rev Ophthalmol 1995; 2:71-74.
  • Blumenkranz MS, Fox GM. Acute Retinal Necrosis, Retina-Vitreous-Macula, D Guyer Ed., WB Saunders 1999; Vol 1, 62:760-765.
  • Vision of the Missouri Optometric Association, “Clinical Trials in Diabetic Retinopathy”, April/May 2001.
  • Mazzuca DE, Shields CL, Sinha N, Bianciotto CG, Fox GM, Shields, JA, "Progressive Retinal Invasion and Vitreous Seeding From Optic Disc Melanocytoma", Clinical and Experimental Ophthalmology 2011.

PRESENTATIONS AND LECTURES (NATIONAL)

  • Association for Research in Vision and Ophthalmology, Annual Meeting, Sarasota FL, May 1986.
  • Association for Research in Vision and Ophthalmology, Annual Meeting, Sarasota, FL, May 1990.
  • Association for Research in Vision and Ophthalmology, Annual Meeting, poster presentation, Sarasota, FL, May 1991.
  • American Academy of Ophthalmology, Long-Acting Gas Intraocular Tamponade in Diabetic Vitrectomy, Dallas, TX, November 1992.
  • Association for Research in Vision and Ophthalmology, Annual Meeting, poster presentation, Sarasota, FL, May 1993.
  • Cataract Surgery Course, Uniformed Services University; Dropped Nuclei., Bethesda, MD, March 1994.
  • Ocular Trauma Course, Uniformed Services University, Sympathetic Ophthalmia, Bethesda, MD, May 1994.
  • American Uveitis Society Meeting, Ocular Lymphoma Mimicking Chronic Postoperative Endophthalmitis, San Francisco, CA, October 1994.
  • Cataract Surgery Course, Uniformed Services University, Posterior Segment Complications of Cataract Surgery, Bethesda, MD, March 1995.
  • Panel Session, FDA, Status of Retinal Devices, Rockville, MD, May 1995.
  • Medical Officer Presentation of VitreonTM and PerfluoronTM, Panel Session, FDA, Rockville, MD, October 1995.
  • Tropical Medicine Course, Uniformed Services University, Ocular Infestations, Bethesda, MD, February 1996.
  • Resident Lecture Series, Temple University, Current Issues in Retinal Diseases, Philadelphia, PA, December 1997.
  • MOA annual convention – October 9, 2000, “Update on Treatment for ARMD”.
  • Optometric Society of Greater Kansas City – February 5, 2001, “Update on Treatment for Complications of Diabetic Retinopathy”.

PRESENTATIONS AND LECTURES (INTERNATIONAL)

  • Master of Science for Clinical Optometry Course, Retinal Diseases: A Primer, Berlin, Germany, February 1997.
  • Master of Science for Clinical Optometry, Ocular Pathology, Oslo, Norway, April 1998.

A Vision to be the Best

As the largest group of Retina specialists in the Greater Kansas City, Topeka, Sedalia and surrounding areas we offer multiple professional offices to serve you.  Each of our offices are staffed and equipped to provide the highest level of health care service and access in a comfortable environment.

Dr. Fox is currently seeing patients at our Shawnee Mission, Kansas City and Lee's Summit locations.

Retina Associates, PA logo

Retina Associates, LLC

Retina Associates, LLC is an advanced medical practice devoted to the diagnosis and treatment of retinal, macular, and vitreous diseases. Together, our eye care physicians belong to various prestigious organizations: 

  • American Board of Ophthalmology
  • American Academy of Ophthalmology
  • Association for Research in Vision and Ophthalmology
  • American College of Surgeons
  • American Society of Retina Specialists

Our mission is to help every patient preserve or restore their sight through our advanced treatment options. To discuss your needs with one of our doctors, request an appointment online or call us at (913) 831-7400.

Contact Us

Rate, Review & Explore

Social Accounts Sprite
Google map image of our location in 8600 Quivira Road Suite 100 Lenexa, KS

Lenexa Office

8600 Quivira Road
Suite 100
Lenexa, KS 66215

Open Today 9:00am - 5:00pm

What is the best time for you?

Add additional time

Tell us a bit about yourself...

(913) 831-7400 Send a message